Forget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trial

MedicalXpress | июл 11, 2026

Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes. The study included adults with Type 2 diabetes who were not taking diabetes medicines and whose blood sugar was not adequately controlled with diet and exercise alone.